CLINICAL RESEARCH: VASCULAR EFFECTS OF NICOTINIC ACID
Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular FunctionA Randomized, Placebo-Controlled, Magnetic Resonance Imaging Study
Justin M.S. Lee, MB, BCh*,
Matthew D. Robson, PhD*,
Ly-Mee Yu, MSc ,
Cheerag C. Shirodaria, MD*,
Colin Cunnington, MBBS*,
Ilias Kylintireas, MD*,
Janet E. Digby, PhD*,
Thomas Bannister, BA*,
Ashok Handa, MB, BS ,
Frank Wiesmann, MD*,
Paul N. Durrington, MD ,
Keith M. Channon, MD*,
Stefan Neubauer, MD* and
Robin P. Choudhury, DM*,*
* Department of Cardiovascular Medicine, University of Oxford and Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Oxford, United Kingdom
Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom
Nuffield Department of Surgery, University of Oxford, Oxford, United Kingdom
Cardiovascular Research Group, University of Manchester, Manchester, United Kingdom
Manuscript received February 3, 2009;
revised manuscript received May 26, 2009,
accepted June 18, 2009.
* Reprint requests and correspondence: Dr. Robin P. Choudhury, Department of Cardiovascular Medicine, Level 6, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom (Email: robin.choudhury{at}cardiov.ox.ac.uk).
Objectives: Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function.
Background: NA raises high-density lipoprotein cholesterol (HDL-C) and reduces low-density lipoprotein cholesterol and is widely used as an adjunct to statin therapy in patients with coronary artery disease. Although changes in plasma lipoproteins suggest potential benefit, there is limited evidence of the effects of NA on disease progression when added to contemporary statin treatment.
Methods: We performed a double-blind, randomized, placebo-controlled study of 2 g daily modified-release NA added to statin therapy in 71 patients with low HDL-C (<40 mg/dl) and either: 1) type 2 diabetes with coronary heart disease; or 2) carotid/peripheral atherosclerosis. The primary end point was the change in carotid artery wall area, quantified by magnetic resonance imaging, after 1 year.
Results: NA increased HDL-C by 23% and decreased low-density lipoprotein cholesterol by 19%. At 12 months, NA significantly reduced carotid wall area compared with placebo (adjusted treatment difference: –1.64 mm2 [95% confidence interval: –3.12 to –0.16]; p = 0.03). Mean change in carotid wall area was –1.1 ± 2.6 mm2 for NA versus +1.2 ± 3.0 mm2 for placebo. In both the treatment and placebo groups, larger plaques were more prone to changes in size (r = 0.4, p = 0.04 for placebo, and r = –0.5, p = 0.02 for NA).
Conclusions: In statin-treated patients with low HDL-C, high-dose modified-release NA, compared with placebo, significantly reduces carotid atherosclerosis within 12 months. (Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function; NCT00232531
[ClinicalTrials.gov]
)
Key Words: carotid atherosclerosis HDL cholesterol magnetic resonance imaging
|
Abbreviations and Acronyms
| | CI = confidence interval | | CRP = C-reactive protein | | HDL-C = high-density lipoprotein cholesterol | | IMT = intima-media thickness | | LDL-C = low-density lipoprotein cholesterol | | MRI = magnetic resonance imaging | | NA = nicotinic acid |
|
Related Articles
-
Assessing Niacin as an Atherosclerosis Therapeutic Agent: Valuable Insights Provided by High-Resolution Vascular Magnetic Resonance Imaging
- Farouc A. Jaffer
J. Am. Coll. Cardiol. 2009 54: 1795-1796.
[Full Text]
[PDF]
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A40.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
F. A. Jaffer
Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
J. Am. Coll. Cardiol.,
November 3, 2009;
54(19):
1795 - 1796.
[Full Text]
[PDF]
|
 |
|
|